|
|
|
|
|
|
|
|
|
|
|
OLIGOMERIX Receives NIH SBIR Grant
|
|
NYC-based OLIGOMERIX has been awarded a Small Business Innovation Research (SBIR) Phase I grant from NIH. The $323,000 grant will seek to develop novel biomarker assays for its drug discovery for Alzheimer's disease (AD). These assays, if validated, may enable disease staging and/or definitive diagnosis of AD.
|
|
|
|
Columbia University Creates Stockbridge Pharmaceuticals
|
|
Newly formed NYC-based Stockbridge Pharmaceuticals has signed a licensing agreement with Columbia University to commercialize a novel small molecule-based approach for the targeted treatment of various cancers. Initial studies of the therapy in a mouse model of basal-like breast cancer tumors have demonstrated significant shrinkage of tumor mass.
|
|
|
|
|
Pfizer to Add Manhattan Employees
|
|
The acquisition of Wyeth by Pfizer, valued at $68B, will result in expanded employment at Pfizer’s Midtown Manhattan offices. Pfizer, headquartered in NYC and the world’s leading drug manufacturer, is planning to fill a 650,000 square foot space it owns in Midtown with employees from Wyeth.
|
|
|
|
Phreesia Raises $11.6M
|
|
Phreesia, a NYC-based developer of healthcare technology, recently raised $11.6M from BlueCross BlueShield Venture Partners and its exclusive fund manager, Sandbox Industries.
Co-founders, Chaim Indig and Evan Roberts, started the company in 2005 after a discussion of the national health care system. In September 2007, Phreesia secured 2nd round funding of $10.25m, bringing total funding to date to roughly $25m.
|
|
|
|
|
Angioblast Systems - Innovation of the Year
|
|
Angioblast Systems’ adult stem cell technology platform was awarded the 2008 Frost & Sullivan United States Stem Cell Market Technology Innovation of the Year for its accuracy in identifying and isolating stem cells. Angioblast Systems, Inc. is a private New York City based biotechnology company committed to the development of novel treatments for cardiac, vascular, and eye conditions.
|
|
|
|
|
NYBA 2009 Annual Meeting
|
|
The 18th Annual New York Biotechnology Association Meeting, will convene on April 20-21 at the New York Marriott Marquis in Times Square. A special rate is still available to help early stage biotech companies attend the meeting. An SBIR panel, featuring JoAnne Goodnight, SBIR/STTR Program Coordinator at NIH, will highlight R&D funding opportunities for bioscience companies.
|
|
|
|
|
|
|
|
|
|
 |
|
Morria Biopharmaceuticals Plc
|
Morria Biopharmaceuticals Plc is a biopharmaceutical company targeting three major inflammatory disease areas: Dermatology, Respiratory, Gastro-intestinal inflammation. With US headquarters in NYC, the company is focused on the development of anti-inflammatory agents termed Multi-Functional Anti-Inflammatory Drugs (MFAID). Morria’s proprietary drug technology platform is based on research originating from leading universities in Israel and the USA.
Morria recently announced positive Phase II data for MRX-4 as an intra-nasal anti-inflammatory drug for allergic rhinitis and has another drug, MRX-6, in Phase II for eczema with three other drugs in advanced pre-clinical stages. “Having achieved so much in under three years and with just $6M, we believe we have a winning strategy to not only survive the current economic turmoil but to thrive in it” said Yuval Cohen, President of Morria.
|
| |
| Back to Top^ |
|
|
|
|
|
|
| LAB LEASING OPPORTUNITIES |
|
|
|
|
|
 |
For more information on the latest Bioscience activities in New York City and how NYCEDC can assist your business, visit us at www.nycbiotech.com or contact Lenzie Harcum at 212-312-3806.
|
|
|
|
|